Lupus Nephritis (LN) Clinical Trials and Treatments

Lupus is an autoimmune disease, and in lupus nephritis the immune attack reaches the glomeruli, the tiny filters that clean the blood. Damaged filters let protein and blood leak into the urine, and over time kidney function can fall. Doctors look for it with urine tests for protein and blood and with blood tests of kidney function.

The most common symptoms of Lupus Nephritis include Foamy urine, from protein leaking into it, Blood in the urine, or brown urine, Swelling in the legs, feet, ankles, hands, face or around the eyes, High blood pressure, Often no symptoms early on, so it is found through urine and blood tests. About 21 per 100,000 people in a Minnesota population study in 2015 (Lupus Midwest Network, 2022). If that rate held across the US it would be roughly 70,000 people, our own estimate, though the study population was mostly white and lupus nephritis is more common in Black, Hispanic and Asian American people. Up to half of adults and 8 in 10 children with lupus develop kidney disease (NIDDK).. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Lupus Nephritis from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. As of October 12, 2026, more than 100 lupus nephritis studies on ClinicalTrials.gov are recruiting or about to start, and most of them test a treatment.

Yes. As of September 2026, Trial Friend lists 3 FDA-approved drugs used to treat Lupus Nephritis: Benlysta (belimumab), first approved in 2011; Gazyva (obinutuzumab), first approved in 2013; and Lupkynis (voclosporin), first approved in 2021.

Each has its own page with what the label covers, side effects and how it is given, and the Treatments section of this page adds any further approved drugs found in FDA labeling data.

The exact cause of Lupus Nephritis is not fully understood. It is not caused by a single gene; inherited variants raise risk, and immune, environmental or other triggers are thought to set it off. Lupus risk comes from many genes acting together with hormones and the environment; single-gene forms of lupus are rare (MedlinePlus Genetics). About 21 per 100,000 people in a Minnesota population study in 2015 (Lupus Midwest Network, 2022). If that rate held across the US it would be roughly 70,000 people, our own estimate, though the study population was mostly white and lupus nephritis is more common in Black, Hispanic and Asian American people. Up to half of adults and 8 in 10 children with lupus develop kidney disease (NIDDK). Research is ongoing to better understand the disease mechanism.

No single gene test diagnoses Lupus Nephritis. The diagnosis rests on clinical findings and laboratory or imaging results; genetic variants shift risk rather than cause the disease. Lupus risk comes from many genes acting together with hormones and the environment; single-gene forms of lupus are rare (MedlinePlus Genetics).

Some trials collect genetic samples for research or check specific risk markers. The Genetic Testing section of this page shows any tests listed in the NIH Genetic Testing Registry, which for this condition are usually research or risk-marker tests rather than diagnostic ones.

Eligibility for Lupus Nephritis clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Lupus Nephritis clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.